Skip to content

Author

F. Zannad

We have 4 of 301 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Sep 2026

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

In ambulatory patients with HFrEF receiving contemporary GDMT, it is not convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for i...

Justin A. Ezekowitz, J. Butler, Derek Cyr et al. · 0 citations
Open access Aug 2026

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Nelson Wang, B. Claggett, M. Pfeffer et al. · 0 citations
Open access Aug 2026

A fully automated machine learning assisted pipeline to predict disease progression for early-stage hypertrophic cardiomyopathy from echocardiography

A fully automated ML model identifies area-derived LACI at end-diastole at end-diastole as a robust feature associated with disease progression, providing improved risk stratification for pre-symptomatic HCM.

Antoine Olivier, Auriane Riou, T. D'humières et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.